Alexion Pharmaceuticals Marketed Drugs - GlobalData
Alexion, Vertex rare disease drugs fare well in new rare disease drug report - Boston Business Journal
MDA Celebrates FDA Approval of Alexion's Ultomiris for Treatment of gMG
Alexion's Soliris wins FDA 'orphan' nod | Hartford Business Journal
Eculizumab - Wikipedia
Alexion Pharmaceuticals: Patented Quality at a Great Price | by Shivam Kollur | Medium
Alexion Says FDA Grants Orphan Drug Designation To ALXN1210 | World Pharma Today
Canadian Drug Watchdog Orders Alexion to Lower Price of Soliris, Refund Overcharges - Global Genes
Can Alnylam execs put the biotech on a path to profitability? - Boston Business Journal
Alexion Pharmaceuticals - Drug Discovery and Development
Justice Department alleges more drug copay kickbacks
Alexion Pharma's Bloated Blockbuster Deal Still Haunts - TheStreet
Alexion Pharmaceuticals to study Ultomiris for Covid-19 treatment
AstraZeneca buys rare disease drugmaker Caelum in potential $500 mln deal | Reuters
AstraZeneca to Acquire Alexion for $39B, Adding Rare Disease, Immunology Assets
Medicines | Alexion
When the Patient Is a Gold Mine: The Trouble With Rare-Disease Drugs - Bloomberg
Medicines | Alexion
Five years later, Alexion sets aside $25M to resolve SEC's foreign bribery probe | Fierce Pharma
Alexion trials rare disease drug Ultomiris in severe COVID-19 cases | Pharmaphorum
Alexion Pharmaceuticals: Revising My Valuation (NASDAQ:ALXN) | Seeking Alpha
Alexion Pharmaceuticals: Patent Resolution Is Too Little Too Late (NASDAQ:ALXN) | Seeking Alpha
Alexion Pharmaceuticals and Moderna Therapeutics Announce Exclusive Strategic Agreement to Develop Messenger RNA Therapeutics™ for Rare Diseases | Business Wire
Alexion tests drug for possible COVID-19 treatment | New Haven BIZ
